Reuters logo
in a month
BRIEF-Amarin says vascepa showed reductions in potentially atherogenic lipid parameters
June 12, 2017 / 11:28 AM / in a month

BRIEF-Amarin says vascepa showed reductions in potentially atherogenic lipid parameters

1 Min Read

June 12 (Reuters) - Amarin Corporation Plc

* Amarin says vascepa showed reductions in potentially atherogenic lipid parameters in statin-treated women with type 2 diabetes and persistent high triglycerides

* Amarin Corp says vascepa significantly increased blood EPA levels

* Amarin Corp - efficacy and safety of vascepa 4 g/day in women were consistent with overall anchor study results

* Amarin Corp expects trial will run to completion and onset of target final primary cardiovascular event will likely be reached near end of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below